Home・Akciju saraksts・Bio-Techne Corp

Bio-Techne Corp

Slēgts

SektorsVeselības aprūpe

72.34 -0.19

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

72.31

Max

72.45

Galvenie mērījumi
By Trading Economics
Ienākumi	3.6M 55M
Pārdošana	9.8M 321M
P/E Sektora vidējais	62.405 57.366
EPS	0.49
Dividenžu ienesīgums	0.44
Peļņas marža	17.006
Darbinieki	3,000
EBITDA	-6.7M 92M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	-0.5% downside

Dividendes
By Acuity
Dividenžu ienesīgums Sektora vidējais	0.44% 2.16%
Nākamie ieņēmumi	2026. g. 4. nov.
Nākamais dividenžu datums	2026. g. 27. nov.
Nākamais Ex dividenžu datums	2026. g. 16. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	42M 11B
Iepriekšējā atvēršanas cena	72.53
Iepriekšējā slēgšanas cena	72.34

Ziņu noskaņojums

By Acuity

50%

126 / 340 Rangs Healthcare

Bio-Techne Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. aug. 19:46 UTC

Correlated Moves

Bio-Techne Corp is trading lower today, reflecting a broader decline in the biotech sector, including Charles River Laboratories International Inc.

2026. g. 27. aug. 23:31 UTC

Bio-Techne Corp shares are higher in after-market hours, though no specific news was identified. Recent economic data showed a decline in initial jobless claims.

2026. g. 19. aug. 19:27 UTC

Correlated Moves

Shares modestly higher, influenced by rise in iShares Biotechnology ETF.

2026. g. 18. aug. 21:41 UTC

Bio-Techne Corp shares are higher in after-market trading, peaking early in the session and remaining near the upper end of their one-month trading range.

2026. g. 17. aug. 19:16 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat amid broader market sentiment, with the Russell 2000 Index declining. Recent economic data has contributed to cautious conditions.

2026. g. 13. aug. 19:16 UTC

Correlated Moves

News

Bio-Techne Corp corrected its dividend record date to August 24, 2026. Shares are trading roughly flat amid broader market dynamics.

2026. g. 5. aug. 19:16 UTC

Correlated Moves

Bio-Techne Corp's shares are lower today, reflecting declines in the Russell 2000 Index. The stock remains near the upper end of its one-month trading range.

2026. g. 4. aug. 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are higher in after-market trading, buoyed by positive sentiment from U.S.-Iran negotiations and gains in major technology stocks.

2026. g. 3. aug. 19:26 UTC

Correlated Moves

Bio-Techne Corp is advancing, reflecting broader market positivity amid gains in major tech stocks and falling energy prices. The stock is near its one-month trading range high.

2026. g. 31. jūl. 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are lower in after-market trading amid a broader market downturn, reflecting negative sentiment impacting price action.

2026. g. 30. jūl. 18:26 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat as the broader market recovers from declines, influenced by rising Treasury yields and inflation concerns.

2026. g. 29. jūl. 22:03 UTC

Bio-Techne Corp shares are lower in after-market hours, reflecting a decline since Wednesday's close amid cautious market sentiment and geopolitical tensions.

2026. g. 20. jūl. 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Salīdzinājums

Cenas izmaiņa

Bio-Techne Corp Prognoze

Cenas mērķis

By TipRanks

-0.5% uz leju

Prognoze 12 mēnešiem

Vidējais 72.11 USD -0.5%

Augstākais 73 USD

Zemākais 65 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Bio-Techne Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Bio-Techne Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

126 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.